Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score

BACKGROUND: Criteria, including clinical features and effective outcomes, for access and persistence of novel but costly treatments may vary between countries, thus affecting the health of patients. Monoclonal antibodies against the calcitonin gene-related peptide pathway (anti-CGRP mAbs) for migrai...

Descripción completa

Detalles Bibliográficos
Autores principales: Iannone, Luigi Francesco, Fattori, Davide, Benemei, Silvia, Chiarugi, Alberto, Geppetti, Pierangelo, De Cesaris, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863684/
https://www.ncbi.nlm.nih.gov/pubmed/35146696
http://dx.doi.org/10.1007/s40263-021-00893-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8863684/
https://www.ncbi.nlm.nih.gov/pubmed/35146696
http://dx.doi.org/10.1007/s40263-021-00893-y

Ejemplares similares